Table 1.

Definitions of appropriate initial anti-TB drug regimen for primary outcome measurement

Case definition*	Appropriate initial anti-TB drug regimen
M. tuberculosis susceptible to rifampicin and isoniazid	Isoniazid + rifampicin + pyrazinamide + ethambutol
M. tuberculosis with mono-resistance to isoniazid	Isoniazid + rifampicin + pyrazinamide + ethambutol
M. tuberculosis with mono-resistance to rifampicin	Standardised second-line regimen§ with isoniazid
Multidrug-resistant M. tuberculosis (MDR-TB)†	Standardised second-line regimen§
Extensively drug-resistant M. tuberculosis (XDR-TB)†	Standardised XDR-TB regimenǁ

* Case definition based on results of MGIT culture + line probe assay + phenotypic DST.

† MDR-TB defined as resistance to rifampicin and isoniazid.

† XDR-TB defined as MDR plus resistance to ofloxacin and kanamycin.

§Standardised regimen according to national guidelines (kanamycin/amikacin + fluoroquinolone + ethionamide + cycloserine/terizidone ± pyrazinamide ± ethambutol) [27].

ǁStandardised regimen according to national guidelines (capreomycin + fluoroquinolone + ethionamide + cycloserine/terizidone + PAS + clofazimine) [27].